Business Wire

VertiGIS Enters Next Phase of Growth, Appoints Andy Berry as CEO

15.11.2022 16:00:00 EET | Business Wire | Press release

Share

VertiGIS, a global market leader and provider of innovative spatial asset management solutions for utilities, telecommunications, government, and infrastructure organizations is entering its next phase of growth and expansion.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221115005035/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

London-based Andy Berry joins VertiGIS as CEO. (Photo: Business Wire)

VertiGIS is backed by global, technology-focused investment firm Battery Ventures, who saw an opportunity to bring together a distributed ecosystem of leading geographic information systems (GIS) and spatial technology companies under the brand in 2017. VertiGIS has since acquired 10 businesses in North America and Europe and shows no signs of slowing down; in fact, the company intends to grow both organically and through acquisition over the coming years to expand VertiGIS’s offerings into their target industries around the world.

Leading the charge for this new phase of rapid growth is London-based Andy Berry, who was recently appointed as VertiGIS’s CEO. Berry has an extensive background in growing global technology companies with executive roles at ZephyrTel, Pitney Bowes, and LogFire. In his most recent role as Executive Vice President (International, Compass Business Unit) at Infor he was responsible for USD $300 million of revenue across seven independent business units with over 100 products that served 20,000 customers in EMEA and Asia.

“It’s impressive to see how VertiGIS has come together and evolved over the past five years,” said Berry. “This next stage of our growth is all about innovation. While our customers can certainly rely upon us to continue supporting them with our trusted, in-market solutions, they can also expect to see us apply our decades of industry experience and research into cutting-edge technology as we continue to invest in configurable, cloud-ready software that solves their real-world challenges.”

Morad Elhafed, a Battery general partner and VertiGIS board member, noted: “We are thrilled to welcome Andy to the team to further VertiGIS’s mission, which has never been more important given recent geopolitical events impacting governments across Europe, a key VertiGIS customer segment. More broadly, we’re excited to support the company’s organic and inorganic growth strategies across all segments and geographies going forward.”

VertiGIS currently employs over 500 employees in nine countries and serves over 5,000 customers – ranging in size from small businesses and municipalities to global enterprises and major cities – around the world. Their proven, configurable solutions address challenges commonly faced by utilities, telecommunications, government, and infrastructure organizations, with use cases such as:

  • Network management (planning, documentation, simulation, analytics);
  • Citizen engagement;
  • Land management and urban planning;
  • Waste management;
  • Facilities and asset management (critical infrastructure, large building operations, commercial spaces, manufacturing plants); and
  • Transportation (roads, rail, airports, seaports).

VertiGIS solutions are powered by the flexible, purposeful capabilities (e.g., web and mobile viewers, reporting and printing designers, fine-grained security tools, intelligent workflows to digitize processes) found in their VertiGIS Studio™ suite, which can also be licensed separately to help customers extend, enhance, or create their own spatial applications quicker with configuration instead of writing costly custom code.

About VertiGIS:

VertiGIS is a leading spatial asset management and geographic information systems (GIS) solution provider and software developer. Its focus is the development of software solutions and services that help utilities, government, telecommunications, and infrastructure professionals connect their business processes to location technology. The VertiGIS product portfolio is used by over 5,000 customers and millions of end-users around the world and is designed to enhance the capabilities of leading mapping software, most notably Esri’s ArcGIS®. Further information at www.vertigis.com.

About Battery Ventures:

Battery strives to invest in cutting-edge, category-defining businesses in markets including software and services, Web infrastructure, consumer Internet, mobile and industrial technologies. Founded in 1983, the firm backs companies at stages ranging from seed to private equity and invests globally from offices in Boston, the San Francisco Bay Area, London, Israel and New York. Follow the firm on Twitter @BatteryVentures, visit our website at www.battery.com and find a full list of Battery's portfolio companies here.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Andy Berry, Chief Executive Officer – VertiGIS
Website: www.vertigis.com
Email: andy.berry@vertigis.com
Phone: +44 (0)7718 118689

Rebecca Buckman, Marketing Partner – Battery Ventures
Website: www.battery.com
Email: becky@battery.com
Phone: +1 650 292 2077

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye